{{Rsnum
|rsid=1881539
|Chromosome=2
|position=200179174
|Orientation=minus
|GMAF=0.1258
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 94.7 | 5.3 | 0.0
| HCB | 59.1 | 40.9 | 0.0
| JPT | 69.0 | 29.2 | 1.8
| YRI | 71.4 | 27.9 | 0.7
| ASW | 78.9 | 21.1 | 0.0
| CHB | 59.1 | 40.9 | 0.0
| CHD | 67.0 | 28.4 | 4.6
| GIH | 92.1 | 7.9 | 0.0
| LWK | 88.2 | 11.8 | 0.0
| MEX | 60.3 | 27.6 | 12.1
| MKK | 84.6 | 15.4 | 0.0
| TSI | 96.1 | 2.9 | 1.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1881539
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.08, combined P value= 1.87E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470206
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1881539
|overall_frequency_n=108
|overall_frequency_d=128
|overall_frequency=0.84375
|n_genomes=55
|n_genomes_annotated=0
|n_haplomes=94
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}